Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

被引:66
|
作者
Bahit, M. Cecilia [1 ]
Lopes, Renato D. [2 ]
Wojdyla, Daniel M. [2 ]
Held, Claes [3 ]
Hanna, Michael [4 ]
Vinereanu, Dragos [5 ]
Hylek, Elaine M. [6 ]
Verheugt, Freek [7 ]
Goto, Shinya [8 ]
Alexander, John H. [2 ]
Wallentin, Lars [3 ]
Granger, Christopher B. [2 ]
机构
[1] INECO, Neurociencias Orono Rosario, Santa Fe, NM, Argentina
[2] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[3] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Med & Pharm Carol Davila, Bucharest, Romania
[6] Boston Univ, Med Ctr, Boston, MA USA
[7] Onze Lieve Vrouwe Gasthuis OLVG, Heartctr, Amsterdam, Netherlands
[8] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
关键词
HEMORRHAGE; DABIGATRAN; THERAPY; STROKE; RISK;
D O I
10.1136/heartjnl-2016-309901
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective We describe the incidence, location and management of non-major bleeding, and assess the association between non-major bleeding and clinical outcomes in patients with atrial fibrillation (AF) receiving anticoagulation therapy enrolled in Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE). Methods We included patients who received >= 1 dose of study drug (n= 18 140). Non-major bleeding was defined as the first bleeding event considered to be clinically relevant non-major (CRNM) or minor bleeding, and not preceded by a major bleeding event. Results Non-major bleeding was three times more common than major bleeding (12.1% vs 3.8%). Like major bleeding, non-major bleeding was less frequent with apixaban (6.4 per 100 patient-years) than warfarin (9.4 per 100 patient-years) (adjusted HR 0.69, 95% CI 0.63 to 0.75). The most frequent sites of non-major bleeding were haematuria (16.4%), epistaxis (14.8%), gastrointestinal (13.3%), haematoma (11.5%) and bruising/ecchymosis (10.1%). Medical or surgical intervention was similar among patients with non-major bleeding on warfarin versus apixaban (24.7% vs 24.5%). A change in antithrombotic therapy (58.6% vs 50.0%) and permanent study drug discontinuation (5.1% (61) vs 3.6% (30), p=0.10) was numerically higher with warfarin than apixaban. CRNM bleeding was independently associated with an increased risk of overall death (adjusted HR 1.70, 95% CI 1.32 to 2.18) and subsequent major bleeding (adjusted HR 2.18, 95% CI 1.56 to 3.04). Conclusions In ARISTOTLE, non-major bleeding was common and substantially less frequent with apixaban than with warfarin. CRNM bleeding was independently associated with a higher risk of death and subsequent major bleeding. Our results highlight the importance of any severity of bleeding in patients with AF treated with anticoagulation therapy and suggest that non-major bleeding, including minor bleeding, might not be minor.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 50 条
  • [21] Risk of stroke and bleeding in atrial fibrillation treated with apixaban compared to warfarin
    Bradley, Marie C.
    Welch, Emily C.
    Eworuke, Efe
    Graham, David
    Zhang, Rongmei
    Huang, Ting-Ying
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 6 - 7
  • [22] Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
    Garcia, David A.
    Wallentin, Lars
    Lopes, Renato D.
    Thomas, Laine
    Alexander, John H.
    Hylek, Elaine M.
    Ansell, Jack
    Hanna, Michael
    Lanas, Fernando
    Flaker, Greg
    Commerford, Patrick
    Xavier, Denis
    Vinereanu, Dragos
    Yang, Hongqiu
    Granger, Christopher B.
    [J]. AMERICAN HEART JOURNAL, 2013, 166 (03) : 549 - 558
  • [23] Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
    Held, Claes
    Hylek, Elaine M.
    Alexander, John H.
    Hanna, Michael
    Lopes, Renato D.
    Wojdyla, Daniel M.
    Thomas, Laine
    Al-Khalidi, Hussein
    Alings, Marco
    Xavier, Dennis
    Ansell, Jack
    Goto, Shinya
    Ruzyllo, Witold
    Rosenqvist, Marten
    Verheugt, Freek W. A.
    Zhu, Jun
    Granger, Christopher B.
    Wallentin, Lars
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (20) : 1264 - 1272
  • [24] A Comparison of Bleeding Events Among Patients on Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism
    Schaefer, Jordan K.
    Errickson, Josh
    Kong, Xiaowen
    Ali, Mona A.
    Chipalkatti, Naina
    Haymart, Brian
    Kaatz, Scott
    Krol, Gregory D.
    Sood, Suman L.
    Froehlich, James
    Barnes, Geoffrey D.
    [J]. BLOOD, 2023, 142
  • [25] Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin
    Lip, G. Y. H.
    Pan, X.
    Kamble, S.
    Kawabata, H.
    Mardekian, J.
    Masseria, C.
    Bruno, A.
    Phatak, H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1085 - 1085
  • [26] Atrial Fibrillation: Apixaban is superior to Warfarin
    Weiss, Johannes
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2012, 80 (02) : 66 - 66
  • [27] Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
    Garcia, David A.
    Fisher, Deborah A.
    Mulder, Hillary
    Wruck, Lisa
    De Caterina, Raffele
    Halvorsen, Sigrun
    Granger, Christopher B.
    Held, Claes
    Wallentin, Lars
    Alexander, John H.
    Lopes, Renato D.
    [J]. AMERICAN HEART JOURNAL, 2020, 221 : 1 - 8
  • [28] Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation
    Zoppellaro, Giacomo
    Granziera, Serena
    Bertozzo, Giulia
    Denas, Gentian
    Marigo, Lucia
    Petruzzellis, Florinda
    Jose, Seena Padayattil
    Rossi, Katia
    Nante, Giovanni
    Pengo, Vittorio
    [J]. THROMBOSIS AND HAEMOSTASIS, 2017, 117 (09) : 1828 - 1830
  • [30] Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation
    Suzuki, Shinya
    Yamashita, Takeshi
    Kato, Takeshi
    Fujino, Tadashi
    Sagara, Koichi
    Sawada, Hitoshi
    Aizawa, Tadanori
    Fu, Long-Tai
    [J]. CIRCULATION JOURNAL, 2007, 71 (05) : 761 - 765